Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple Turns 50: From Garage Startup to AI Crossroads 
Britain Courts Anthropic Amid US Defense Department Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
BRIDGEWATER, N.J., Sept. 08, 2016 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the following investor conferences taking place in New York City:
- Will Lewis, president and chief executive officer, will participate in an analyst-led fireside chat on Tuesday, September 13 at 3:30 PM ET at the Morgan Stanley Global Healthcare Conference.
- Mr. Lewis will also participate in an analyst-led fireside chat on Wednesday, September 28 at 9:00 AM ET at the Leerink Partners Rare Disease Roundtable.
The presentations will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed’s earlier-stage clinical pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company believes may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma. To complement its internal research, Insmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information, visit www.insmed.com.
“Insmed” and “ARIKAYCE” are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Insmed Incorporated: Susan Mesco Head of Investor Relations 908-947-4326
